AstraZeneca Pharmaceuticals LP
73 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Recorded under 4 name spellings.
4
Ending by 2030
Apr 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 1 fee due Dec 11, 2026The maintenance fee for Therapeutic Dendrimers (US 10,314,920) comes due Dec 11, 2026. Unpaid by Jun 11, 2027, it lapses early.
Recent changes
- 3 terms have ended since Aug 17, 2026
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,389,472 | EXENDIN-4 to Treat Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease In force · High confidence | In force | High confidence | |
| US 8,497,240 | DPP-IV Resistant GIP Hybrid Polypeptides with Selectable Properties In force · Medium confidence | In force | Medium confidence | |
| US 8,946,149 | Use of Exendin and Analogs Thereof To Delay or Prevent Cardiac Remodeling In force · High confidence | In force | High confidence | |
| US 8,895,033 | Sustained Release Formulations Using Non-Aqueous Carriers In force · High confidence | In force | High confidence | |
| US 9,382,304 | Engineered polypeptides having enhanced duration of action with reduced immunogenicity In force · From the USPTO record | In force | From the USPTO record | |
| US 9,018,381 | Chemical Compounds In force · High confidence | In force | High confidence | |
| US 10,149,839 | Chemical Compounds In force · High confidence | In force | High confidence | |
| US 10,131,663 | Chemical Compounds In force · High confidence | In force | High confidence | |
| US 10,221,173 | Chemical Compounds In force · High confidence | In force | High confidence | |
| US 10,314,920 | Therapeutic Dendrimers In force · High confidence | In force | High confidence |
Also on record, not counted in the 11: 73 patents in force now held by others · 37 lapsed for an unpaid fee · 13 ended at full term · 1 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
3 pending · 12 abandoned · 28 no status recorded